Prostate Cancer Foundation Release: Abiraterone Phase III Clinical Trial Data to Be Highlight of ESMO Meeting

Published: Oct 08, 2010

SANTA MONICA, Calif.--(BUSINESS WIRE)--Attendees at next week’s European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer. This new drug is the latest breakthrough for the treatment of advanced cases and is the first-in-class intracrine androgen antagonist for patients whose cancer has stopped responding to androgen deprivation therapy (ADT).

Back to news